Phase III Flop in Schizophrenia; Top Psych Hospitals; Doubts on Cannabis Addiction
Ulotaront, an investigational trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, flopped in two phase III studies for schizophrenia, though developers Sumitomo Pharma